GLP-1类似物利拉鲁肽研究进展  

Advance of glicagon like peptide-1 liraglutide

作　　者：侯永春[1] 郭绍来[1] 

机构地区：[1]解放军总医院药品保障中心,北京100853

出　　处：《中国药物应用与监测》2012年第1期50-53,共4页Chinese Journal of Drug Application and Monitoring

摘　　要：胰高糖素样肽-1类似物(GLP-1类似物)利拉鲁肽是一种全新作用机制的降糖药物,具有降低体重、降低收缩压、改善胰岛细胞功能。本文对利拉鲁肽国内外近期文献进行分析,从其药理作用特点、临床研究、安全性和耐受性等方面阐述其研究进展。其长期应用疗效如何以及能否延缓糖尿病的进展仍需要进一步的研究。Liraglutide, glicagon like peptide-1 （GLP-1）, was a new antidiabetic drug with a different mechanism, which had some effect on decreasing body weight, depressing systolic pressure and improving islet cell function. We collected the articles of glicagon published in Chinese and abroad, and the progress of liraglutide from pharmacologic action, clinical research, safety and survivability were elaborated. The efficacy in long-term and postpone the progress of diabetes should be studied further.

关 键 词：胰高糖素样肽-1类似物 利拉鲁肽 进展 降糖药物 

分 类 号：R977.15[医药卫生—药品]